Home | Welcome to Contract Pharma   
Last Updated Sunday, May 19 2013
Print RSS Feed

Breaking News

Related Searches: Financial Reports •
Financial Report: Cambrex Corp. 4Q

February 12, 2009
Sales in the quarter were up 1% excluding the impact of foreign exchange. Sales of controlled substances increased due to higher demand, offset by decreases due to delays in certain custom development projects, lower sales of generic APIs, and lower contr  Read More »
Financial Report: Genzyme 4Q

February 11, 2009
Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%).  Read More »
Financial Report: Sanofi-Aventis 4Q

February 11, 2009
Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%).  Read More »
Sanofi-Aventis

February 11, 2009
Jean-Pierre Lehner, M.D., has been appointed senior vice president, chief medical officer, Sanofi-Aventis. Dr. Lehner reports to Marc Cluzel, senior vice president, R&D.   Read More »
Financial Report: Elan

February 10, 2009
Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition.  Read More »
Financial Report: Charles River Laboratories 4Q

February 10, 2009
Preclinical Services (PCS) segment revenue was $158.6 million (-8%) due to slower market demand and the negative impact of foreign exchange.  Read More »
Halo Pharmaceutical

February 10, 2009
Halo Pharmaceutical has named Allen M. Rosenston vice president of business development.  Read More »
Financial Report: AMRI 4Q

February 9, 2009
Contract revenue for the quarter, which includes Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing, was $49.6 million (+22%) and $195.5 million for the year (+20%).  Read More »
ATryn Approved by the FDA

February 9, 2009
GTC Biotherapeutics and Ovation Pharmaceuticals, Inc. received approval from the FDA for ATryn (Antithrombin [Recombinant]) for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.  Read More »
Velesco Pharmaceutical Services

February 9, 2009
Peter Angus, Pharm.D., Ph.D., and Lisa Crandall, MS have joined the scientific team at Velesco Pharmaceutical Services, a CRO supporting early stage product development for pharmaceutical companies.  Read More »
Financial Report: Biogen Idec 4Q

February 6, 2009
Growth was driven by Tysabri sales, up 74% to $156 million in the quarter and up 156% to $589 million for the year.  Read More »
Idenix, GSK Sign Worldwide HIV Pact

February 6, 2009
Idenix Pharmaceuticals has entered a license agreement granting GlaxoSmithKline (GSK) exclusive worldwide rights to IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development for the treatment of HIV/AIDS.  Read More »
J&JPRD Files Schizophrenia Drugs

February 6, 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted multiple applications to the FDA for the treatment of schizophrenia.   Read More »
Financial Report: GlaxoSmithKline 4Q

February 5, 2009
Pharmaceutical sales in the quarter were $9.3 billion (-9%) and $37.7 billion for the year (-2%). Advair sales were $2.8 billion in the quarter (+47%) and $10.8 billion for the year (+54%).  Read More »
MiddleBrook Retains Almac for Packaging Services

February 5, 2009
MiddleBrook Pharmaceuticals has retained Almac Pharma Services to provide packaging services for physician samples of Moxatag (amoxicillin extended-release) Tablets. Almac will work closely with MiddleBrook's commercial manufacturer, STADA Production Irel  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: